Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease
- PMID: 33995923
- PMCID: PMC8105181
- DOI: 10.1016/j.csbj.2021.04.035
Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease
Abstract
An appropriate therapeutic index is crucial for drug discovery and development since narrow therapeutic index (NTI) drugs with slight dosage variation may induce severe adverse drug reactions or potential treatment failure. To date, the shared characteristics underlying the targets of NTI drugs have been explored by several studies, which have been applied to identify potential drug targets. However, the association between the drug therapeutic index and the related disease has not been dissected, which is important for revealing the NTI drug mechanism and optimizing drug design. Therefore, in this study, two classes of disease (cancers and cardiovascular disorders) with the largest number of NTI drugs were selected, and the target property of the corresponding NTI drugs was analyzed. By calculating the biological system profiles and human protein-protein interaction (PPI) network properties of drug targets and adopting an AI-based algorithm, differentiated features between two diseases were discovered to reveal the distinct underlying mechanisms of NTI drugs in different diseases. Consequently, ten shared features and four unique features were identified for both diseases to distinguish NTI from NNTI drug targets. These computational discoveries, as well as the newly found features, suggest that in the clinical study of avoiding narrow therapeutic index in those diseases, the ability of target to be a hub and the efficiency of target signaling in the human PPI network should be considered, and it could thus provide novel guidance in the drug discovery and clinical research process and help to estimate the drug safety of cancer and cardiovascular disease.
Keywords: Artificial intelligence; Cancer; Cardiovascular disease; Drug mechanism; Narrow therapeutic index.
© 2021 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Determining the Balance Between Drug Efficacy and Safety by the Network and Biological System Profile of Its Therapeutic Target.Front Pharmacol. 2018 Oct 31;9:1245. doi: 10.3389/fphar.2018.01245. eCollection 2018. Front Pharmacol. 2018. PMID: 30429792 Free PMC article.
-
Narrow Therapeutic Index drugs: clinical pharmacology perspective.J Pharm Pharmacol. 2021 Sep 7;73(10):1285-1291. doi: 10.1093/jpp/rgab102. J Pharm Pharmacol. 2021. PMID: 34347858 Review.
-
Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations.Clin Pharmacol Ther. 2025 Jan;117(1):116-129. doi: 10.1002/cpt.3460. Epub 2024 Nov 11. Clin Pharmacol Ther. 2025. PMID: 39529254 Review.
-
Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan.Int J Clin Pharm. 2015 Dec;37(6):1235-41. doi: 10.1007/s11096-015-0194-0. Epub 2015 Sep 23. Int J Clin Pharm. 2015. PMID: 26399507
-
Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients.Pharm Pract (Granada). 2010 Jan;8(1):50-5. doi: 10.4321/s1886-36552010000100006. Epub 2010 Mar 15. Pharm Pract (Granada). 2010. PMID: 25152793 Free PMC article.
Cited by
-
Calculation of Integral Indicators of the Metabolic Status and Filtration Function of Kidneys in Patients with a Combat Mine-Explosive Injury who Lost Significant Body Weight due to Limb Amputation.Acta Med Litu. 2025;32(1):64-77. doi: 10.15388/Amed.2025.32.1.2. Epub 2025 Feb 18. Acta Med Litu. 2025. PMID: 40641548 Free PMC article.
-
Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents.Nucleic Acids Res. 2022 Jan 7;50(D1):D1398-D1407. doi: 10.1093/nar/gkab953. Nucleic Acids Res. 2022. PMID: 34718717 Free PMC article.
-
Altered striatal dopamine regulation in ADGRL3 knockout mice.bioRxiv [Preprint]. 2025 Aug 1:2025.07.31.667389. doi: 10.1101/2025.07.31.667389. bioRxiv. 2025. PMID: 40766670 Free PMC article. Preprint.
-
An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.Stat Med. 2024 Feb 20;43(4):689-705. doi: 10.1002/sim.9980. Epub 2023 Dec 18. Stat Med. 2024. PMID: 38110304 Free PMC article.
-
VARIDT 2.0: structural variability of drug transporter.Nucleic Acids Res. 2022 Jan 7;50(D1):D1417-D1431. doi: 10.1093/nar/gkab1013. Nucleic Acids Res. 2022. PMID: 34747471 Free PMC article.
References
-
- Yu L.X., Jiang W., Zhang X., Lionberger R., Makhlouf F. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286–291. - PubMed
-
- Muller P.Y., Milton M.N. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751–761. - PubMed
-
- Krens S.D., Lassche G., Jansman F.G.A., Desar I.M.E. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e207. - PubMed
-
- Chen L., Chu C., Zhang Y.-H., Zheng M., Zhu L. Identification of drug-drug interactions using chemical interactions. Curr Bioinform. 2017;12(6):526–534.
LinkOut - more resources
Full Text Sources
Other Literature Sources